HONOLULU, HI —At the American Pain Society’s 31st Annual Scientific Meeting, investigators reported that a 5-minute application of NGX-1998, a novel liquid formulation of high concentration capsaicin (10% and 20% w/w) provided effective pain relief for up to 12 weeks for the management of peripheral neuropathic pain associated with postherpetic neuralgia (PHN).  

Capsaicin 8% (Qutenza) is available in a patch formulation that provides 12 weeks of PHN pain relief following a single 60-minute application. NGX-1998 was studied in a 12-week, multicenter, placebo-controlled, double-blind trial in PHN patients to determine if it could deliver similar or better efficacy, safety, and tolerability following a 5-minute application. Using a 2:2:1 (10%: 20%: placebo) randomization, 164 patients received a 5-minute topical application of NGX-1998 or placebo to their area of pain. The primary endpoint was mean percent change from baseline in average pain for the past 24 hours during Weeks 2–8; secondary endpoint was the mean percent change during Weeks 2–12.

Using the Numeric Pain Rating Scale (NPRS), patients recorded their scores daily during Weeks 2–12.   A clear dose-response was observed in the mean percent change in average pain from baseline at Week 8: -25.1%, -22.3%, and -16.7% for the NGX-1998 20%, 10%, and placebo groups, respectively. At week 12, mean percent change in average pain was -26.0%, -22.2%, and -16.6% for the 20%, 10%, and placebo groups, respectively. The study was not powered to determine a statistically significant difference between the 20% and 10% formulations.

The patients’ dermal assessment scores ranged from 0–2 (0=no irritation, 1=mild erythema, 2= definite erythema, minimal papules/edema). The most common adverse effects were localized dermal reactions (eg, pain and erythema). Severe and serious adverse effects were more prevalent in the placebo group. NGX-1998 was well-tolerated at both doses and resulted in improved outcomes on validated measures of neuropathic pain.


Continue Reading

Lynn Webster, MD, from Lifetree Clinical Research, Salt Lake City, UT, and colleagues, concluded that a 5-minute application of NGX-1998 may provide a convenient option to patients with PHN that could reduce healthcare provider time.